Arvinas, Inc.

Is Arvinas, Inc. technically bullish or bearish?

As of October 3, 2025, Arvinas, Inc. shows a neutral technical trend with mixed signals, outperforming the S&P 500 in the short term but significantly underperforming year-to-date.

As of 3 October 2025, the technical trend for Arvinas, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Moving averages are mildly bearish on the daily timeframe. Dow Theory is mildly bullish for both weekly and monthly periods. <BR><BR>In terms of performance, Arvinas has outperformed the S&P 500 over the past week and month, with returns of 12.78% and 22.86% respectively, but has significantly underperformed over longer periods, including a year-to-date return of -49.82% compared to the S&P 500's 14.18%.

Is Arvinas, Inc. overvalued or undervalued?

As of August 6, 2025, Arvinas, Inc. is considered risky and overvalued due to unfavorable metrics, including a Price to Book Value of 0.83, a negative P/E ratio of -10.12, and a year-to-date return of -59.73%, significantly underperforming compared to its peers and the S&P 500.

As of 6 August 2025, the valuation grade for Arvinas, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.83 and an EV to EBITDA ratio of 13.10, which are not favorable compared to its peers. Additionally, the ROCE stands at 12.11%, while the ROE is negative at -10.12%, further highlighting the company's struggles.<BR><BR>In comparison to its peers, Arvinas, Inc. has a P/E ratio of -10.12, while Vir Biotechnology, Inc. and Xencor, Inc. have P/E ratios of -1.4151 and -3.2519, respectively, indicating that Arvinas is underperforming relative to its industry. The stock has also significantly lagged behind the S&P 500, with a year-to-date return of -59.73% compared to the index's 12.22%. This stark contrast reinforces the notion that Arvinas, Inc. is currently overvalued.

How big is Arvinas, Inc.?

As of Jun 18, Arvinas, Inc. has a market capitalization of 545.98 million, with net sales of 324.50 million and a net profit of 2.60 million over the last four quarters.

Market Cap: As of Jun 18, Arvinas, Inc. has a market capitalization of 545.98 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Arvinas, Inc. reported net sales of 324.50 million and a net profit of 2.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company had shareholder's funds of 561.70 million and total assets amounting to 1,091.40 million.

What does Arvinas, Inc. do?

Arvinas, Inc. is a biopharmaceutical company focused on developing therapies that degrade disease-causing proteins. As of March 2025, it reported net sales of $189 million and a market cap of approximately $546 million.

Overview:<BR>Arvinas, Inc. is a development-stage biopharmaceutical company engaged in the development and commercialization of therapies to degrade disease-causing proteins, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 189 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 83 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 545.98 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.44 <BR>Return on Equity: -10.12% <BR>Price to Book: 0.83<BR><BR>Contact Details:<BR>Address: 5 Science Park, NEW HAVEN CT: 06511-1966 <BR>Tel: 1 203 5351456 <BR>Fax: 1 302 6365454 <BR>Website: http://arvinas.com/

Should I buy, sell or hold Arvinas, Inc.?

Who are in the management team of Arvinas, Inc.?

As of March 2022, the management team of Arvinas, Inc. includes Dr. Timothy Shannon (Independent Chairman), Dr. John Houston (President and CEO), and several directors: Ms. Linda Bain, Dr. Wendy Dixon, Mr. Edward Kennedy, Mr. Bradley Margus, and Dr. Briggs Morrison. The team features a blend of executive leadership and independent directors.

As of March 2022, the management team of Arvinas, Inc. includes the following individuals:<BR><BR>- Dr. Timothy Shannon, who serves as the Independent Chairman of the Board.<BR>- Dr. John Houston, who is the President, Chief Executive Officer, and Director.<BR>- Ms. Linda Bain, who is a Director.<BR>- Dr. Wendy Dixon, who is also a Director.<BR>- Mr. Edward Kennedy, serving as an Independent Director.<BR>- Mr. Bradley Margus, another Independent Director.<BR>- Dr. Briggs Morrison, who is also an Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors.